logo
'Doctors said I only had two years to live'

'Doctors said I only had two years to live'

Yahoo26-01-2025
When Marsha McCarty-Coombs was diagnosed with Conn's Syndrome at the age of 39, doctors told her to "get her papers in order" as she may have less than two years left to live. Now at 59, she has surpassed all health expectations.
"I'm just so happy and grateful to be alive," said Marsha, who is originally from Bristol but now lives in London.
Conn's Syndrome, also known as primary aldosteronism, is a condition that causes high blood pressure due to excessive production of the hormone aldosterone by the adrenal glands.
She has launched an affordable jewellery brand as a way to give back to the community of Bristol by raising money for local charities.
Marsha's battle began in 2005 when she collapsed at her London home and was rushed to hospital.
Despite spending six months at Park Royal Hospital, doctors were unable to identify the cause of her illness.
"They told me to go home and get my papers in order because they didn't believe I would live to see 40," Marsha recalled.
But instead of preparing for the worst, she planned a family reunion and a 40th birthday celebration, determined to embrace life.
After enduring numerous tests and consultations, she was finally diagnosed with Conn's Syndrome.
The Cleveland Clinic estimates that 5% to 10% of adults with high blood pressure have this condition, which is more prevalent in women.
Symptoms include low potassium levels, high blood pressure, headaches, muscle cramps and excessive thirst.
However, many individuals, including Marsha, do not recognise the symptoms.
"When they diagnosed me, I wasn't looking for symptoms. I just thought it was early menopause," she said.
The condition led to severe complications, including uncontrolled bleeding that led to a hysterectomy.
Marsha has since also been diagnosed with Cushing's Syndrome, another hormonal disorder caused by excessive cortisol levels.
This condition has led to the development of non-cancerous tumours, including two found on her brain and another on her vocal gland.
Due to the risk of spreading, doctors have opted not to remove the latter.
Despite her health struggles, Marsha said she tries to remain positive.
She founded an affordable jewelry brand, Queens of Jewellery, to support low-income families while raising funds for charities across the West of England.
Her products range from 50p to £25, ensuring accessibility for all.
"As a single mum, I know the struggle of choosing between a loaf of bread and treating yourself.
"I wanted to create something affordable for everyone," she explained.
Her efforts have supported charities such as Missing Link, a Bristol-based domestic abuse organisation.
Marsha said managing her condition has been challenging but she has now reduced her medication intake from 32 tablets a day to eight with the support of a pharmacist.
"I go into hospital every six months for tests, and every year my consultant reminds me that I shouldn't still be here," she said.
Despite losing her hair, mobility, and battling arthritis, Marsha said she remains calm.
"I've learned how to deal with pain, and I'm just so grateful to be alive," she said.
She said her husband has been a constant source of strength, standing by her side without "coddling" her.
Follow BBC Bristol on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Amy Schumer reveals she has Cushing's Syndrome
'My whole world went to bits after ME diagnosis'
'I was diagnosed with endometriosis by chance'
Cushing's syndrome - NHS
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Epoch Times

time6 hours ago

  • Epoch Times

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.

Unlocking Cellular Health With Science and Trust
Unlocking Cellular Health With Science and Trust

Los Angeles Times

time9 hours ago

  • Los Angeles Times

Unlocking Cellular Health With Science and Trust

In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an unwavering commitment to responsible innovation Niagen Bioscience (NASDAQ: NAGE, formerly Chromadex) is a Los Angeles-based company dedicated to advancing the supplements industry using science-backed research into their component ingredients. At the helm is CEO Robert Fried, who says the company's mission is to pioneer NAD+ research and develop transformative NAD-boosting healthy-aging solutions with Niagen, their patented form of nicotinamide riboside (NR). Niagen is the cornerstone of the company's clinically proven product portfolio, Tru Niagen and Niagen IV and injections. During this year's Cannes Lions, Fried sat down with LA Times Studios to discuss how the company is pioneering the NAD+ space and the science and quality backed benefits of its Niagen products. 'NAD+, or nicotinamide adenine dinucleotide, is a co-enzyme found in all living cells – plant and animal – and is involved in all important metabolic processes within the cell, but especially energy metabolism and DNA repair, which are key to supporting mitochondrial health and overall optimal health.' explained Fried. Mitochondria, the 'battery pack of the cell,' combines nutrients from the food you eat and oxygen with NAD+ to produce energy. NAD+ also plays a crucial role in DNA recovery and cellular repair. 'All of these processes that exist within the cell where the cell repairs damage are NAD+ dependent,' Fried emphasized, illustrating how higher NAD+ levels facilitate rapid healing, contrasting youthful recovery with a slower healing process that occurs as we age. This is because NAD+ starts to decline naturally in our 30s, with research showing a dramatic drop of up to 65% by the time we reach age 70. Exposure to stressors like sedentary lifestyle, excess sun exposure, poor diet and environmental factors also impact NAD+ levels. Research shows that NAD+ decline is associated with a decline in overall health and vitality, contributing to the development of conditions and disease. Fried is quick to address a significant industry misconception: 'NAD+ itself is not bioavailable. If you consume NAD+ orally or with an IV, it will not elevate NAD+ levels inside your cells.' He clarified that the NAD+ molecule is too large to penetrate cells, causing NAD+ supplements and IV to be ineffective. Intact NAD+ may even have the potential to cause acute immune inflammatory response, which may be responsible for the uncomfortable side effects associated with NAD+ IV and injections. The solution, according to Fried, is 'to consume an NAD+ precursor molecule that easily gets into the cell and then converts into NAD+, and the best molecule for this is called nicotinamide riboside or NR.' Niagen is patented NR and precisely what Tru Niagen and pharmaceutical-grade Niagen IV and injections offer. With a legacy spanning over 25 years, the company's recent rebranding from ChromaDex to Niagen Bioscience reflects its sharpened focus. 'We're no longer only a reference standards company but an NAD+ company dedicated to addressing one of life's most complex challenges - aging,' said Fried. Niagen Bioscience differentiates itself by operating as an 'R&D lab that specializes in NAD+,' not simply a supplement distributor, he said. Its distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and an external research program helping independent investigators and institutions worldwide uncover the potential of NAD+. 'There is no other company in the supplement space that comes close this level of R&D investment and scientific research,' Fried asserted. The company boasts 38 peer-reviewed, published human clinical studies on oral food-grade Niagen, of which about 95% are completely independent, with another 40 studies currently underway. This level of scientific rigor, he contends, is typically found only in biotech or pharmaceutical companies. Products are tested at the manufacturing facility and then retested upon delivery. Fried notes their marketing: 'We are real. We are genuine. We let the science do the talking.' This approach, he believes, is key to building genuine trust. Niagen Bioscience is exploring Niagen's broader therapeutic potential for its patented NR. Fried reveals extensive clinical studies on the benefits of its patented food-grade NR for specific age-related and orphan diseases (rare conditions characterized by rapid aging). Some of these studies have reached Phase II and III clinical trials. A 52 week, 400-participant, Phase III double-blinded, controlled study on Parkinson's disease recently concluded, conducted with a world-renowned independent researcher. 'That is a level of scientific research ... that you don't see from supplement companies,' Fried emphasized. Niagen Bioscience is also innovating beyond oral supplements. They've developed a pharmaceutical-grade version of nicotinamide riboside, now available as Niagen IV. exclusively at clinics across the U.S. Fried highlighted its advantages: 'If you do an injection or an IV, you're getting the benefits of Niagen directly to the bloodstream.' This results in faster absorption and avoids side effects often associated with direct NAD+ infusions. Fried candidly addresses his concern about a lack of public trust in the dietary supplement industry, citing prevalent unsubstantiated claims, low-quality products, and marketing hype. 'It's my belief that if people genuinely trusted the companies that the industry at large would be so significant because we'd actually have preventative health value,' he states. To combat this, Niagen Bioscience has proposed a 'Trust Alliance' – a coalition of industry players, government and non-profits to test products and ensure claims are met. For Fried, the most meaningful aspect of his journey is receiving letters from individuals who experienced health benefits after taking Tru Niagen. Looking ahead, Niagen Bioscience aims to solidify its position as the 'gold standard in the NAD+ space,' continuing its scientific leadership. 'Our mission is to help every living being around the world age better. We think what could happen in the next five years is very exciting and special,' Fried concluded.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store